Legend Biotech (LEGN) Research & Development (2019 - 2025)
Legend Biotech (LEGN) posted Research & Development of -$101.3 million for Q4 2025, up 10.47% on a QoQ basis from -$113.1 million in Q3 2025, and up 2.97% year-over-year from -$98.4 million in Q4 2024.
Legend Biotech (LEGN) has 7 years of Research & Development data on file, last reported at -$101.3 million in Q4 2025.
- In Q4 2025, Research & Development rose 2.97% year-over-year to -$101.3 million; the TTM figure through Dec 2025 stood at -$414.7 million (changed 0.28% YoY), while the FY2025 annual figure was -$414.7 million, changed 0.29% from the prior year.
- Research & Development rose to -$101.3 million in Q4 2025, from -$113.1 million in the prior quarter.
- Across five years, Research & Development topped out at -$71072.0 in Q1 2021 and bottomed at -$113.1 million in Q3 2025.
- A 5-year average of -$84.1 million and a median of -$95.7 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development sank 114639.98% — and 2023, when it surged 99.87%.
- Year by year, Research & Development stood at -$86.5 million in 2021, then grew by 6.64% to -$80.8 million in 2022, then surged by 99.87% to -$105683.0 in 2023, then sank by 98685.99% to -$104.4 million in 2024, then climbed by 2.97% to -$101.3 million in 2025.
- The last three Research & Development figures came in at -$101.3 million (Q4 2025), -$113.1 million (Q3 2025), and -$98.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 343.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -101.30 Mn |
| Sep 30, 2025 | -113.15 Mn |
| Jun 30, 2025 | -98.30 Mn |
| Mar 31, 2025 | -101.92 Mn |
| Dec 31, 2024 | -104.40 Mn |
| Sep 30, 2024 | -95.52 Mn |
| Jun 30, 2024 | -112.63 Mn |
| Mar 31, 2024 | -100.96 Mn |
| Dec 31, 2023 | -105,683.00 |
| Sep 30, 2023 | -95.86 Mn |
| Jun 30, 2023 | -95.79 Mn |
| Mar 31, 2023 | -84.89 Mn |
| Dec 31, 2022 | -80.76 Mn |
| Sep 30, 2022 | -104.52 Mn |
| Jun 30, 2022 | -68.83 Mn |
| Mar 31, 2022 | -81.55 Mn |
| Dec 31, 2021 | -86.50 Mn |
| Sep 30, 2021 | -72.31 Mn |
| Jun 30, 2021 | -83.46 Mn |
| Mar 31, 2021 | -71,072.00 |
| Dec 31, 2020 | -66.93 Mn |
| Sep 30, 2020 | -63.66 Mn |
| Jun 30, 2020 | -53.57 Mn |
| Mar 31, 2020 | -48.00 Mn |
| Dec 31, 2019 | -66.10 Mn |
| Sep 30, 2019 | -41.92 Mn |
| Jun 30, 2019 | -32.64 Mn |